Achmea Investment Management B.V. Sells 2,438 Shares of Cencora, Inc. $COR

Achmea Investment Management B.V. lessened its holdings in Cencora, Inc. (NYSE:COR) by 2.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 111,504 shares of the company’s stock after selling 2,438 shares during the period. Achmea Investment Management B.V.’s holdings in Cencora were worth $33,435,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Cornerstone Planning Group LLC lifted its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after purchasing an additional 48 shares during the period. Costello Asset Management INC bought a new position in shares of Cencora in the 1st quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cencora in the 1st quarter worth approximately $39,000. Finally, Hantz Financial Services Inc. lifted its stake in shares of Cencora by 712.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 2.4%

Cencora stock opened at $352.83 on Thursday. The stock has a market cap of $68.41 billion, a P/E ratio of 36.30, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $361.38. The firm’s 50 day moving average price is $311.49 and its 200-day moving average price is $298.36.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is 22.63%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on COR. UBS Group increased their price objective on shares of Cencora from $350.00 to $380.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Evercore ISI set a $340.00 target price on shares of Cencora in a research note on Wednesday, October 8th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Finally, Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $329.55.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.